[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-362433-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-362433-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","early-termination-of-nct04617067-phase-ii-open-label-clinical-trial-of-oral-paricalcitol-combination","Early termination of NCT04617067 - phase II open-label clinical trial of oral paricalcitol combination","","Pancreatic ductal adenocarcinoma shows poor response to chemotherapy, leaving a clear unmet need for new treatments. This phase II, single-arm study assessed the safety and tolerability of oral paricalcitol given with systemic chemotherapy in patients with advanced disease. Gemcitabine and NAB-paclitaxel were administered weekly, while paricalcitol was dosed daily across a 28-day cycle. Fifteen patients were enrolled; the trial was stopped early after interim analysis due to failing the prespecified 6-month PFS probability threshold.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/early-termination-of-nct04617067-phase-ii-open-label-clinical-trial-of-oral-paricalcitol-combination/362433/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/early-termination-of-nct04617067-phase-ii-open-label-clinical-trial-of-oral-paricalcitol-combination/362433.png","ImageObject",300,407,{"name":42,"@type":43},"Jacob","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-19","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the purpose of the phase II trial involving paricalcitol?","Question",{"text":63,"@type":64},"To evaluate the safety and tolerability of oral paricalcitol combined with systemic chemotherapy in patients with advanced pancreatic ductal adenocarcinoma.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were the study drugs administered during the 28-day cycle?",{"text":68,"@type":64},"Gemcitabine and NAB-paclitaxel were given weekly for 3 of every 4 weeks (days 1, 8, and 15), while paricalcitol was administered orally every day of the 28-day cycle.",{"name":70,"@type":61,"acceptedAnswer":71},"Why was the trial terminated early?",{"text":72,"@type":64},"The study did not meet its primary objective; after the planned interim analysis criterion for proceeding was not met, the trial was discontinued.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},362433,1790203564,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":113,"preview_page_count":33,"preview_urls":145},962084931830,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Easty et al. BMC Cancer (2026) 26:255 BMC Cancer  \n[https://doi.org/10.1186/s12885-025-14512-2](https://doi.org/10.1186/s12885-025-14512-2)  \nRESEARCH Open Access  \nEarly termination of NCT04617067, a phase II, open label, clinical trial of oral paricalcitolin combination with gemcitabine and NABpaclitaxel therapy in advanced pancreatic cancer  \nDavid Easty1,2,3*, Ray McDermott4, Adrian G. Murphy2, Liam Grogan2, Patrick G. Morris2, Oscar S. Breathnach2, Keith Egan2, Sinead Toomey5, Anne Horgan6, Derek Power7, Nemer Osman8, Imelda Parker1, Vicky Donachie1, Anna Shevlin1, Aisling Barrett1, Marc Nolan1, Jacinta Marron1, Christine J. Farr9 and BryanT. Hennessy 1,2  \nAbstract  \nBackground Pancreatic cancer (PDAC) often responds poorly to chemotherapy, represents an unmet clinical need and new therapeutic approaches are urgently required. Desmoplasia is a hallmark of PDAC. Multiple preclinical studies suggest cancer associated fibroblasts (CAF) support cancer growth, and attention has recently turned towards inclusion of anti-stromal agents into chemotherapy trials. Our objective was to evaluate safety and tolerability of oral paricalcitol in combination with systemic chemotherapy in patients with advanced PDAC.  \nMethods This was a phase II, single-arm study in patients with advanced PDAC who had received no prior systemic chemotherapy. Gemcitabine and NAB-paclitaxel were administered weekly for 3 of every 4 weeks (days 1, 8 and 15) and paricalcitol administered orally every day of a 28-day cycle. Patients were treated until disease progression with an interim analysis. The primary efficacy endpoint was progression free survival (PFS) . Secondary efficacy endpoints were evaluation of overall survival (OS), time to treatment failure (TTF) and tumour response rate (TRR) .  \nResults Fifteen patients were enrolled. Median PFS was 14.6 weeks with 95% CI of (7 .9–24. 0) . Estimated PFS rate at 24 weeks was 18. 0% with 95% CI of (2 .9–43.4) . Five patients achieved stable disease; one achieved a partial response. Confirmed tumour response rate was 8. 3% with 90% CI of (0 .4–33. 9) . Mild hypercalcaemia, previously associated with vitamin D receptor agonists, occurred in nine (60%) patients, moderate (Grade 3) hypercalcaemia in 2 patients and there was no grade 4/5 hypercalcaemia. The study did not meet its primary objective and discontinued following interim analysis.  \nConclusions Oral paricalcitol was safely combined with chemotherapy. The prespecified efficacy threshold for 6-month progression free survival probability (≥ 70%) was not met. The study was stopped early after the planned  \n*Correspondence:  \nDavid Easty [david.easty@cancertrials.ie](david.easty@cancertrials.ie)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nEasty et al. BMC Cancer (2026) 26:255 Page 2 of 12  \ninterim ana","cbCaisPMEAxnTbsr","https://ap.wps.com/l/cbCaisPMEAxnTbsr","pdf",2530673,"English","# Background\n## Study methods\n## Results\n## Conclusions\n# Trial registration and keywords","[{\"question\":\"What was the purpose of the phase II trial involving paricalcitol?\",\"answer\":\"To evaluate the safety and tolerability of oral paricalcitol combined with systemic chemotherapy in patients with advanced pancreatic ductal adenocarcinoma.\"},{\"question\":\"How were the study drugs administered during the 28-day cycle?\",\"answer\":\"Gemcitabine and NAB-paclitaxel were given weekly for 3 of every 4 weeks (days 1, 8, and 15), while paricalcitol was administered orally every day of the 28-day cycle.\"},{\"question\":\"Why was the trial terminated early?\",\"answer\":\"The study did not meet its primary objective; after the planned interim analysis criterion for proceeding was not met, the trial was discontinued.\"}]","Early termination of NCT04617067 - phase II open-label clinical trial of oral paricalcitol combination | PDF",1790147735,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/80b3e61da53845c1645664e3b3d6c861.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/144da26971570436cd4cb3a4ec2d806f.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/25a238eb91518ca67391f8825c2442e5.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/45017af7b6fe7dbab852b331ee4d7454.webp",980,1306]